Author

Johanna Nimmerfroh

University of Basel

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Assay:CITE-seq· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

Christoph SchultheißiD· 2 shared Heinz Philipp LaubliiD· 2 shared Mascha BinderiD· 2 shared Alfred ZippeliusiD· 1 shared Anastasiya BörschiD· 1 shared Andreas ZinggiD· 1 shared Anne EugsteriD· 1 shared Benjamin KasendaiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Christoph SchultheißORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

alpha2,3-sialylation on human naive T cells restrains bispecific engager-mediated anti-tumor immunity

Johanna Nimmerfroh, Dinah Heiligensetzer, Michael T. Sandholzer, Anastasiya Börsch, Andreas Zingg, Christoph Schultheiß, Mascha Binder, Rafael Martínez-Carrasco, Pablo Argüeso, Alfred Zippelius, Luana Guerra, Heinz Philipp Laubli

Desialylation enhances bispecific T cell engager responses by relieving a sialoglycan-dependent restraint in human T cells.

bioRxiv · Aug 6, 2026 · PreprintImmunology

IGLV3-21-R110-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia

Claudia Fischer, Shih‐Shih Chen, Johanna Nimmerfroh, Anne Eugster, Simon Stücheli, Christoph Schultheiß, Corinne C. Widmer, Dominik Heim, Benjamin Kasenda, Jakob Robert Passweg, Sebastian Kobold, Lukas Egli, Nicolò Coianiz, Obinna Chijioke, Nicholas Chiorazzi, , Mascha Binder

This study develops bispecific antibodies targeting IGLV3-21R110 to selectively kill high-risk CLL cells while sparing healthy B cells and stem cells.

Haematologica · Sep 11, 2025Peer-reviewedCancer Biology